+++Summary of earnings this morning, 30.07.+++
$BP. (+1,3 %) achieves an EBIT (adjusted) of $5.41 billion (analyst forecast: $5.52 billion) and a net profit of $2.76 billion (forecast: $2.69 billion) in Q2. The dividend for the 2nd quarter is expected to be 8 cents per share (forecast: 7.8 cents). BP plans to buy back shares with a volume of $3.5 bn in the second half of the year.
-
Redcare Pharma $RDC (+2,27 %) achieved sales of €560.67 million in the 2nd quarter (previous year: €419.9 million) and EBITDA (adjusted) of €15.04 million (previous year: €13.25 million). A net profit of €12.57 million (previous year: -€14.4 million) was reported in the first half of the year. Outlook confirmed.
-
Fuchs $FPE (+0,3 %) achieved sales of €1.76 billion (previous year: €1.82 billion, analyst forecast: €1.76 billion), EBIT of €218 million (previous year: €200 million, forecast: €217.6 million) and net profit of €155 million (previous year: €141 million) in the first half of the year. Outlook confirmed.
-
Covestro $1COV (+0,14 %) achieved sales of €3.69 billion in the second quarter (previous year: €3.72 billion, analyst forecast: €3.69 billion), EBITDA of €320 million (previous year: €385 million, forecast: €311 million) and a net result of -€72 million (previous year: €46 million, forecast: €14 million). In the outlook for 2024, Covestro is adjusting its forecast and now sees free operating cash flow of -€100 to +€100 million (previously: €0 to €300 million, analyst forecast: €173 million) and EBITDA of €1.0 to €1.4 billion (previously: €1.0 to €1.6 billion, forecast: €1.25 billion).
-
Heidelberg Materials $HEI (+0,46 %) achieved sales of €5.51 billion in Q2 (previous year: €5.58 billion, analyst forecast: €5.55 billion) and EBIT (adjusted) of €971 million (previous year: €931 million, forecast: €981 million). Outlook for 2024 confirmed.
-
Fresenius Medical Care $FME (+1,24 %) achieves sales (adjusted) of €4.74 billion (previous year: €4.74 billion), operating income (adjusted) of €433 million (previous year: €400 million, forecast: €433 million) and net income (adjusted) of €207 million (previous year: €176 million, forecast: €201 million) in the second quarter. Forecast confirmed.
